Onco Wiki / Indication

Papillary thyroid carcinoma (PTC) · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Trackstandard
Linked regimenNone
IDIND-AUTOIMMUNE-THYROIDITIS-LYMPHOMA-PREVENTION-SURVEILLANCE
TypeIndication
Statusreviewed 2026-05-18 | pending_clinical_signoff
DiseasesDIS-THYROID-PAPILLARY
SourcesSRC-NCCN-BCELL-2025 SRC-NCCN-THYROID-2025

Notes

STUB — v0.3 chronic-condition prevention pilot (Hashimoto's thyroiditis). Two-Co-Lead signoff queued. PTC risk magnitude in Hashimoto's remains debated (2-3x vs surveillance-bias-attenuated); surveillance cadence reflects the higher-confidence lymphoma signal + the modest PTC nodule-emergence pattern. Future enhancement: a dedicated DIS-THYROID-LYMPHOMA entity would allow more precise Indication anchoring than the current DIS-THYROID-PAPILLARY + DIS-BURKITT pair.

Used By

Indication

Red flag